Okay, let's tackle this question about ocriplasmin. The user provided the question and correct answer, but the options are missing. Hmm, that's a problem. Wait, maybe they forgot to include the options. Let me think. Ocriplasmin is a drug I remember being used for a specific eye condition. From what I recall, it's related to the vitreous and retinal issues.

Ocriplasmin is a recombinant protease, so it's probably breaking down some protein. The main use I remember is for vitreomacular adhesion. Vitreomacular adhesion can lead to complications like macular holes or epiretinal membranes. The drug works by cleaving fibronectin, which is part of the vitreoretinal interface, helping to separate the vitreous from the macula. That makes sense because the vitreous gel normally adheres to the retina, and if it doesn't detach properly, it can cause issues.

Now, the options aren't provided, so I need to hypothesize what the possible options might be. Common conditions treated with ocriplasmin include vitreomacular adhesion, diabetic retinopathy, age-related macular degeneration, or maybe something else. Let's say the options are A. Diabetic retinopathy, B. Age-related macular degeneration, C. Vitreomacular adhesion, D. Retinal detachment. In that case, the correct answer would be C.

Why is it correct? Because ocriplasmin is specifically indicated for vitreomacular adhesion when there's no macular hole. It's a single-dose intravitreal injection. The enzyme breaks down the fibronectin, reducing the adhesion. The other options are treated with different drugs. Diabetic retinopathy and macular degeneration often use anti-VEGF agents like ranibizumab. Retinal detachment is usually treated surgically, not with proteases.

Wait, but I need to make sure. Ocriplasmin isn't used for all vitreoretinal issues. It's a specific indication. The clinical pearl here is that ocriplasmin is for vitreomacular adhesion, not for other retinal conditions. Students might confuse it with anti-VEGF drugs, so it's important to distinguish the uses. The key is the mechanism of action—protease cleaving fibronectin, which is specific to vitreomacular adhesion.

**Core Concept**
Ocriplasmin is a recombinant serine protease (plasmin derivative) that cleaves fibronectin in the vitreoretinal interface. It is specifically indicated for vitreomacular adhesion (VMA) without macular hole, reducing traction and promoting anatomical resolution.

**Why the Correct Answer is Right**
Vitreomacular adhesion occurs when the vitreous gel adheres abnormally to the macula, causing traction that may lead to macular holes or epiretinal membranes. Ocriplasmin's proteolytic activity targets fibronectin, a key component of the vitreoretinal adhesion complex. By enzymatically cleaving this protein, it facilitates posterior vitreous detachment, relieving traction and improving visual outcomes. It is administered as a single intravitreal

✓ Correct Answer: C. Uveovitreal membrane (Vitreoretinal) adhesion